Tazemetostat

Generic Name: Tazemetostat

Brand Names: Tazverik

Drug Type: Small Molecule

Chemical Formula: C_₃₄H_₄₄N_₄O_₄

CAS Number: 1403254-99-8

Unique Ingredient Identifier: Q40W93WPE1

Background: Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438.

Tazemetaostat was granted FDA approval on 23 January 2020.

Indication: Tazemetostat is indicated to treat adult and pediatric patients 16 years and older with metastatic or locally advanced epithelioid sarcoma that is not eligible for complete resection. It is also indicated to treat adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an IZH2 mutation and who have received at least 2 pri...

Associated Conditions: Locally Advanced Epithelioid Sarcoma, Metastatic Epithelioid Sarcoma, Refractory Follicular Lymphoma, Relapsed Follicular Lymphoma

Associated Therapies: -

Clinical Trials

SEC Charges Ipsen Worker for Insider Trading Tied to $247M Epizyme Acquisition

Ipsen employee Dishant Gupta charged with insider trading after allegedly profiting from stock transactions based on non-public knowledge of the company's $247 million buyout of Epizyme. Gupta, who agreed to plead guilty, faces a monetary penalty and is barred from serving as an executive or director of any publicly traded company. Ipsen's oncology portfolio expansion includes acquisitions like Epizyme's Tazverik and Merrimack Pharmaceuticals' Onivyde, along with deals for cancer drug development programs.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy